for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Progenics Pharmaceuticals, Inc.

PGNX.OQ

Latest Trade

5.25USD

Change

0.01(+0.19%)

Volume

8,279

Today's Range

5.21

 - 

5.30

52 Week Range

3.43

 - 

6.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.24
Open
5.21
Volume
8,279
3M AVG Volume
21.36
Today's High
5.30
Today's Low
5.21
52 Week High
6.54
52 Week Low
3.43
Shares Out (MIL)
86.42
Market Cap (MIL)
452.85
Forward P/E
-5.58
Dividend (Yield %)
--

Next Event

Progenics Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Velan Capital Launches Consent Solicitation To Reconstitute Progenics Pharma Board

Altiva Management Says Progenics Board Has Been Unreceptive To Efforts To Reach Resolution

Progenics Pharmaceuticals Q2 Loss Per Share $0.23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Industry

Biotechnology & Drugs

Contact Info

1 World Trade Ctr Fl 47

+1.646.9752500

http://www.progenics.com/

Executive Leadership

Peter J. Crowley

Independent Chairman of the Board

Mark Robert Baker

Chief Executive Officer, Director

Patrick Fabbio

Chief Financial Officer, Senior Vice President

Vivien Wong

Executive Vice President - Development

Benedict Osorio

Senior Vice President - Quality

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

0.150

2017

-0.730

2018

-0.870

2019(E)

-0.939
Price To Earnings (TTM)
--
Price To Sales (TTM)
19.86
Price To Book (MRQ)
6.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
57.95
LT Debt To Equity (MRQ)
49.97
Return on Investment (TTM)
-60.32
Return on Equity (TTM)
-52.49

Latest News

BRIEF-Progenics Asserts Ownership Of PSMA-617 Intellectual Property, Including Composition Of Matter Patent

* PROGENICS ASSERTS OWNERSHIP OF PSMA-617 INTELLECTUAL PROPERTY, INCLUDING COMPOSITION OF MATTER PATENT

FDA approves Progenics' treatment for rare adrenal gland tumors

The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.

FDA approves Progenics' treatment for two rare tumors

The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors.

BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement

* PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT

BRIEF-Progenics Pharmaceuticals Announces Q1 Loss Per Share $0.19

* PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)

BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404

* PROGENICS PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PSMA-TARGETED IMAGING AGENT 1404 Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma

* PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA

BRIEF-Progenics Pharmaceuticals Q3 loss per share $0.22

* Progenics Pharmaceuticals announces third quarter 2017 financial results and business update

BRIEF-Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

* Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra

BRIEF-Progenics Pharmaceuticals Q2 loss per share $0.24

* Progenics Pharmaceuticals announces second quarter 2017 financial results and business update

BRIEF-Progenics Pharmaceuticals reports Q1 loss per share $0.23

* Progenics pharmaceuticals announces first quarter 2017 financial results and business update

BRIEF-Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®

* Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra®

BRIEF-Progenics Pharmaceuticals posts Q4 loss per share $0.10

* Progenics Pharmaceuticals announces fourth quarter and full-year 2016 financial results and business update

BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment

* Progenics Pharmaceuticals announces initiation of a phase 1 clinical trial of its PSMA-targeted therapeutic candidate 1095 for the treatment of metastatic prostate cancer Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald

* Entered controlled equity offering sales agreement with Cantor Fitzgerald, pursuant to which Co may offer, sell up to $75 million stock Source text for Eikon: Further company coverage:

BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing

* Progenics Pharmaceuticals Inc - files for mixed shelf of up to $250 million - SEC filing Source text: (http://bit.ly/2jcUEzy) Further company coverage:

BRIEF-Progenics announces $50 million RELISTOR royalty-backed financing

* Progenics announces $50 million RELISTOR royalty-backed financing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up